FORCE’s eXamining the Relevance of Articles for Young Survivors (XRAYS) program is a reliable resource for breast cancer research-related news and information. XRAYS reviews new breast cancer research, provides plain-language summaries, and rates how the media covered the topic. XRAYS is funded by the CDC.
Men with breast cancer
Triple negative breast cancer
Her2+ breast cancer
People with a genetic mutation linked to cancer risk
Breast cancer survivors
Women under 45
Women over 45
Healthy people with average cancer risk
Special populations: Women who have or are considering breast implants
In March 2017, the Food and Drug Administration reported that patients with breast implants may be at increased risk for a rare type of lymphoma. This was covered in a previous XRAYS review. The FDA has continued to collect data since the first reported association in 2011. Recently, the agency released an update on the number of reported cases of breast implant-associated lymphoma and lifetime risk estimates for women with textured breast implants. (04/02/18)
|At a glance||In-depth|
|Findings||What does this mean for me?|
|Questions for your doctor||Resources and references|
An update to a previous FDA report on the increased risk of anaplastic large cell lymphoma, a rare type of non-Hodgkin lymphoma, in women who have breast implants.
Patients who are making decisions about breast reconstruction or breast augmentation should be informed of any possible link between anaplastic large cell lymphoma (ALCL) and breast implants. Healthcare providers should also be aware of this link so they can properly monitor women who have breast implants.
Previously, the FDA had received 359 medical device reports (also known as adverse event reports), including 9 deaths, of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). Of these:
As of September 2017, the FDA had received a total of 414 medical device reports of BIA-ALCL, including the death of nine patients.
While the number of cases of BIA-ALCL has increased, the number of deaths remains the same. It is important to note that most cases occurred in individuals who have textured-surface implants, and that no association has been made between BIA-ALCL and the interior material (saline or silicone) of the implant. Nor is there an association with breast cancer. BIA-ALCL is as likely to occur in women who choose implants for cosmetic reasons as it is in women who choose them for breast reconstruction following a mastectomy.
Recent reports estimate that the lifetime risk of developing BIA-ALCL ranges from between 1 in 3,817 to 1 in 30,000 for women with textured implants.
The FDA no longer recognizes BIA-ALCL as a rare condition (instead, it reports estimated risk). However, while it is not known how many women currently have breast implants, it is important to note that in the United States an estimated 450,000 women get breast implants each year. Considering the number of women who receive breast implants, the risk for BIA-ALCL is very low.
The FDA is still collecting data; as new data is added it may impact current risk estimates. Since the FDA began collecting data, the known risk has increased and this trend may continue as more data comes in.
Breast implants come in different sizes and shapes, have different types of fillings (silicone or saline) and have either smooth or textured surfaces (shells). BIA-ALCL appears to develop more frequently with textured implants than smooth-surfaced implants. Before getting breast implants, talk to your health care provider about the benefits and risks of both textured-surface and smooth-surfaced implants.
Patients who are concerned about possible long-term complications of implant reconstruction should be aware of alternatives such as flap reconstruction or no reconstruction. If you are interested in alternative options, discuss these with your health care provider.
If you already have breast implants, there is no need to change your routine medical care, and currently, removing breast implants is not currently recommended by the FDA if you do not show signs or symptoms of BIA-ALCL (unless you develop unrelated issues with your breast implants). According to the FDA report, the most common symptom of BIA-ALCL is swelling around the implant, which can occur from 2 to 28 years after surgery. You should also contact your health care provider if you notice redness, pain, lumps or breast asymmetry.
Note: On 07/25/19, the FDA announced a recall of Allergan BIOCELL textured implants and expanders, due to their association with BIA-ALCL.
Share your thoughts on this XRAYS article by taking our brief survey
FORCE Conference: Our annual Joining FORCEs conference offers sessions on mastectomy with and without breast reconstruction, access to plastic surgeons and our Show & Tell Room where women who are considering mastectomy can meet women who have undergone mastectomy with and without reconstruction.
FORCE Information: Breast Reconstruction
FORCE Information: Postmastectomy Photo Gallery
FORCE XRAYS: After mastectomy: Reconstruct or not?
FORCE Blog: Post-Reconstruction Thoughts on “Going Flat”
FORCE Blog: After Mastectomy: Go Flat or Reconstruct
Be Empowered Webinar: Breast Reconstruction Options
FORCE Publications: Show and Tell Book
The Breast Reconstruction Guidebook: Issues and Answers from Research to Recovery, 4th Edition by Kathy Steligo
U.S. Food and Drug Administration. “Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL).” Published on March 2018.
FORCE XRAYS. "FDA report claims women with breast implants may be at risk for rare cancer." Published April 17, 2017.